Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $350
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 Pipeline Review, H2 2017
Summary
According to the recently published report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Pipeline Review, H2 2017'; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 Phosphatidylinositol4, 5bisphosphate 3kinase catalytic subunit beta isoform is an enzyme encoded by the PIK3CB gene. It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulinreceptor substrate IRS proteins. It is required for lymphatic vasculature development, different signaling pathways for stable platelet adhesion and aggregation. It plays an important role in platelet activation.
The report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Pipeline Review, H2 2017' outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 3 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology and Ophthalmology which include indications Solid Tumor, Breast Cancer, Diffuse Large BCell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme GBM, Lymphoma, Ovarian Cancer, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Multiple Myeloma Kahler Disease, Neuroblastoma, Pancreatic Cancer, Prostate Cancer, Refractory Chronic Lymphocytic Leukemia CLL, Thyroid Cancer, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Anaplastic Thyroid Cancer, Burkitt Lymphoma, CNS Lymphoma, Colorectal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor GIST, Hepatocellular Carcinoma, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Lung Cancer, Mantle Cell Lymphoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Transitional Urothelial Tract Cancer, Myelofibrosis, NonHodgkin Lymphoma, NonSmall Cell Lung Cancer, NUT Midline Carcinoma NMC or Nuclear Protein in Testis Midline Carcinoma, Papillary Thyroid Cancer, PostPolycythemia Vera Myelofibrosis PPVMF, Primary CNS Lymphoma, Recurrent Glioblastoma Multiforme GBM, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia CLL, Renal Cell Carcinoma, Squamous NonSmall Cell Lung Cancer, Thrombocythemia Myelofibrosis, Thrombosis and Thymoma Thymic Epithelial Tumor.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153
The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 targeted therapeutics and enlists all their major and minor projects
The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
